You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.
The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.
Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.
This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.
The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.
Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.
The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.
In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.
AstraZeneca has released its coronavirus vaccine trial protocol, according to the New York Times.
According to the Guardian, more than 150 countries have signed on to a global SARS-CoV-2 vaccine plan.
Time magazine looks into how liquid biopsies are changing cancer care.
In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.
The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.
The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.
A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.
In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.
Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.
A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.
In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.
CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.